Humoral response to catumaxomab correlat
✍
Marion G. Ott; Frederik Marmé; Gerhard Moldenhauer; Horst Lindhofer; Michael Hen
📂
Article
📅
2011
🏛
John Wiley and Sons
🌐
French
⚖ 893 KB
The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (__n__ = 258) with malignant ascites, catumaxomab showed a clear clinical benefit __vs__. paracentesis and had an acceptable safety pr